These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36680159)

  • 21. On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy.
    Focosi D; Franchini M; Casadevall A
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
    Yue S; Li Z; Lin Y; Yang Y; Yuan M; Pan Z; Hu L; Gao L; Zhou J; Tang J; Wang Y; Tian Q; Hao Y; Wang J; Huang Q; Xu L; Zhu B; Liu P; Deng K; Wang L; Ye L; Chen X
    Front Immunol; 2021; 12():751584. PubMed ID: 34630430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients.
    Kasten MJ; Lahr BD; Parisapogu A; Yetmar ZA; O'Horo JC; Orenstein R; Moreno Franco P; Razonable RR; Vergidis P; Shah AS; Enzler MJ; Inwards DJ; Bauer PR
    Sci Rep; 2023 Dec; 13(1):21249. PubMed ID: 38040756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response.
    Marconato M; Abela IA; Hauser A; Schwarzmüller M; Katzensteiner R; Braun DL; Epp S; Audigé A; Weber J; Rusert P; Schindler E; Pasin C; West E; Böni J; Kufner V; Huber M; Zaheri M; Schmutz S; Frey BM; Kouyos RD; Günthard HF; Manz MG; Trkola A
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35482408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing monoclonal antibodies for treatment of COVID-19.
    Taylor PC; Adams AC; Hufford MM; de la Torre I; Winthrop K; Gottlieb RL
    Nat Rev Immunol; 2021 Jun; 21(6):382-393. PubMed ID: 33875867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons.
    Tzou PL; Tao K; Pond SLK; Shafer RW
    PLoS One; 2022; 17(3):e0261045. PubMed ID: 35263335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.
    Weisser M; Khanna N; Hedstueck A; Sutter ST; Roesch S; Stehle G; Sava M; Deigendesch N; Battegay M; Infanti L; Holbro A; Bassetti S; Pargger H; Hirsch HH; Leuzinger K; Kaiser L; Vu DL; Baur K; Massaro N; Busch MP; Simmons G; Stone M; Felgner PL; de Assis RR; Khan S; Tsai CT; Robinson PV; Seftel D; Irsch J; Bagri A; Buser AS; Corash L
    Transfusion; 2022 Oct; 62(10):1997-2011. PubMed ID: 36054476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies.
    Janssen M; Leo A; Wolf C; Stenzinger M; Bartenschlager M; Brandt J; Sauer S; Schmitt M; Dreger P; Schlenk RF; Denkinger CM; Müller-Tidow C
    Int J Cancer; 2024 Aug; 155(4):618-626. PubMed ID: 38721724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
    Richier Q; De Valence B; Chopin D; Gras E; Levi LI; Abi Aad Y; Pacanowski J; Meynard JL; Plaçais L; Fey D; Couture P; Martin-Blondel G; Pestre V; Woessner J; Ancellin S; Weyrich P; Carpentier B; Idri S; Tiberghien P; Surgers L; Hueso T; Lacombe K
    Influenza Other Respir Viruses; 2024 Mar; 18(3):e13272. PubMed ID: 38501337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID 19 convalescent plasma: Is there still a place for CCP?
    Moog R
    Transfus Apher Sci; 2023 Apr; 62(2):103680. PubMed ID: 36870907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab).
    Siripongboonsitti T; Nontawong N; Tawinprai K; Suptawiwat O; Soonklang K; Poovorawan Y; Mahanonda N
    Microbiol Spectr; 2023 Dec; 11(6):e0325723. PubMed ID: 37975699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.